Share on StockTwits

Intercept Pharmaceuticals (NASDAQ:ICPT) CEO Mark Pruzanski sold 10,000 shares of the stock on the open market in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $250.61, for a total value of $2,506,100.00. Following the completion of the transaction, the chief executive officer now directly owns 475,042 shares of the company’s stock, valued at approximately $119,050,276. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Several analysts have recently commented on the stock. Analysts at Goldman Sachs initiated coverage on shares of Intercept Pharmaceuticals in a research note on Wednesday. They set a “neutral” rating and a $265.00 price target on the stock. Separately, analysts at RBC Capital initiated coverage on shares of Intercept Pharmaceuticals in a research note on Monday. They set an “outperform” rating and a $425.00 price target on the stock. Finally, analysts at Summer Street reiterated a “buy” rating on shares of Intercept Pharmaceuticals in a research note on Friday, June 27th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $457.56.

Intercept Pharmaceuticals (NASDAQ:ICPT) traded down 0.50% on Thursday, hitting $244.98. 171,897 shares of the company’s stock traded hands. Intercept Pharmaceuticals has a one year low of $42.41 and a one year high of $497.00. The stock has a 50-day moving average of $257.2 and a 200-day moving average of $279.8. The company’s market cap is $5.166 billion.

Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($1.59) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.72) by $0.87. On average, analysts predict that Intercept Pharmaceuticals will post $-14.92 earnings per share for the current fiscal year.

Intercept Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver diseases utilizing its bile acid chemistry.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.